DrugPatentWatch Database Preview
NASONEX Drug Profile
Which patents cover Nasonex, and when can generic versions of Nasonex launch?
This drug has forty-six patent family members in thirty-three countries.
The generic ingredient in NASONEX is mometasone furoate. There are twenty-nine drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the mometasone furoate profile page.
Summary for NASONEX
International Patents: | 46 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Suppliers / Packagers: | 4 |
Bulk Api Vendors: | 57 |
Clinical Trials: | 44 |
Patent Applications: | 4,126 |
Formulation / Manufacturing: | see details |
Drug Prices: | see details |
DailyMed Link: | NASONEX at DailyMed |

Pharmacology for NASONEX
Drug Class | Corticosteroid |
Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Medical Subject Heading (MeSH) Categories for NASONEX
Synonyms for NASONEX
(11beta,16alpha)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate |
(11beta,16alpha)-9,21-Dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methylpregna-1,4-diene-3,20-dione |
(1R,2S,10S,11S,13R,14R,15S,17S)-1-CHLORO-14-(2-CHLOROACETYL)-17-HYDROXY-2,13,15-TRIMETHYL-5-OXOTETRACYCLO[8.7.0.0(2),?.0(1)(1),(1)?]HEPTADECA-3,6-DIEN-14-YL FURAN-2-CARBOXYLATE |
(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl furan-2-carboxylate |
(9beta,10alpha,11alpha,14beta,16alpha,17alpha)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate |
[(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloranyl-17-(2-chloranylethanoyl)-10,13,16-trimethyl-11-oxidanyl-3-oxidanylidene-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate |
[(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate |
04201GDN4R |
11?,16?)-9,21-Dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl 2-furoate |
2-furancarboxylic acid [(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloro-1-oxoethyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] ester |
83919-23-7 |
9,21-dichloro-11beta-hydroxy-16alpha-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate |
9,21-Dichloro-11beta,17-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 17-(2-furoate) |
919M237 |
A840685 |
AB2000407 |
AC-941 |
AC1L9AZS |
AK163902 |
AKOS015994732 |
AN-15438 |
Asmanex |
Asmanex HFA |
Asmanex Twisthaler |
BC228151 |
BDBM50148733 |
BPBio1_000424 |
BRD-K60640630-001-03-7 |
BRN 4340538 |
BSPBio_000384 |
C07817 |
C27H30Cl2O6 |
CAS-83919-23-7 |
CCG-220572 |
CHEBI:47564 |
CHEMBL1161 |
CS-2389 |
D00690 |
Danitin |
DR003147 |
DSSTox_CID_3333 |
DSSTox_GSID_23333 |
DSSTox_RID_76981 |
DTXSID4023333 |
Ecural |
Elocon |
Elocone |
Elomet |
Flumeta |
HMS1569D06 |
HMS2096D06 |
HMS2235I14 |
HY-13693 |
KS-00000SPL |
KS-1275 |
LAS 41002 |
M2354 |
MLS002153879 |
MolPort-003-849-257 |
Mometasone 17-(2-furoate) |
mometasone 17-furoate |
mometasone furancarboxylate |
mometasone furoate |
Mometasone furoate (JAN/USP) |
Mometasone furoate [USAN:USP:JAN] |
Mometasone furoate hydrate |
Mometasone Furoate Impurity G |
MOMETASONE FUROATE MONOHYDRATE |
Mometasone furoate, >=98% (HPLC) |
Mometasone furoate, European Pharmacopoeia (EP) Reference Standard |
Mometasone Furoate, pharmaceutical secondary standard; traceable to USP, PhEur and BP |
Mometasone furoate, United States Pharmacopeia (USP) Reference Standard |
Monovo |
NCGC00016950-01 |
NCGC00179578-01 |
NCGC00179578-03 |
NCGC00179578-04 |
Nosorex |
NSC-746171 |
NSC746171 |
Ovixan |
PL071566 |
Pregna-1,20-dione, 9,21-dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)- |
Pregna-1,4-diene-3,20-dione, 9,21-dichloro-17-((2-furanylcarbonyl)oxy)-11-hydroxy-16-methyl-, (11beta,16alpha)- |
Prestwick_924 |
Prestwick0_000572 |
Prestwick1_000572 |
Prestwick2_000572 |
Prestwick3_000572 |
Q-101380 |
Rimelon |
s1987 |
Sch 32088 |
Sch-32088 |
SCHEMBL4568 |
Sinuva |
SMR001233233 |
SPBio_002603 |
SR-01000841209 |
SR-01000841209-2 |
ST24048112 |
TL8005500 |
Tox21_110705 |
Tox21_110705_1 |
UNII-04201GDN4R |
WOFMFGQZHJDGCX-ZULDAHANSA-N |
ZINC3938677 |
US Patents and Regulatory Information for NASONEX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Merck Sharp Dohme | NASONEX | mometasone furoate | SPRAY, METERED;NASAL | 020762-001 | Oct 1, 1997 | AB | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | |||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for NASONEX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Merck Sharp Dohme | NASONEX | mometasone furoate | SPRAY, METERED;NASAL | 020762-001 | Oct 1, 1997 | ➤ Try a Free Trial | ➤ Try a Free Trial |
Merck Sharp Dohme | NASONEX | mometasone furoate | SPRAY, METERED;NASAL | 020762-001 | Oct 1, 1997 | ➤ Try a Free Trial | ➤ Try a Free Trial |
Merck Sharp Dohme | NASONEX | mometasone furoate | SPRAY, METERED;NASAL | 020762-001 | Oct 1, 1997 | ➤ Try a Free Trial | ➤ Try a Free Trial |
Merck Sharp Dohme | NASONEX | mometasone furoate | SPRAY, METERED;NASAL | 020762-001 | Oct 1, 1997 | ➤ Try a Free Trial | ➤ Try a Free Trial |
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for NASONEX
Drugname | Dosage | Strength | RLD | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Nasal Spray | 50 mcg/ Spray | ➤ Subscribe | 2009-08-07 |
Non-Orange Book US Patents for NASONEX
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
Patent No. | Title | Estimated Patent Expiration |
---|---|---|
6,180,781 | Process for making mometasone furoate monohydrate | ➤ Try a Free Trial |
Patent No. | Title | Estimated Patent Expiration |
International Patents for NASONEX
Country | Document Number | Estimated Expiration |
---|---|---|
China | 1059911 | ➤ Try a Free Trial |
Norway | 300548 | ➤ Try a Free Trial |
Hungary | 9300685 | ➤ Try a Free Trial |
Luxembourg | 90366 | ➤ Try a Free Trial |
Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for NASONEX
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|
C0002 | Belgium | ➤ Try a Free Trial | PRODUCT NAME: MOMETASONE FUROATE; NAT. REGISTRATION NO/DATE: NL 19601 19950919; FIRST REGISTRATION: GR - 10681/89 19900622 |
1998 | Austria | ➤ Try a Free Trial | PRODUCT NAME: MOMETASON FUROAT MONOHYDRAT; NAT. REGISTRATION NO/DATE: 1-22208 19971111; FIRST REGISTRATION: FR AMM 343012.6 19970219 |
875032 | Germany | ➤ Try a Free Trial | PRODUCT NAME: MOMETASON-FUROAT-MONOHYDRAT; NAT. REGISTRATION NO/DATE: 40803.00.00 19980218; FIRST REGISTRATION: FRANKREICH NL 22055 19970219 |
5/1998 | Austria | ➤ Try a Free Trial | PRODUCT NAME: MOMETASON FUROAT MONOHYDRAT |
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |